ESR1 Data Fuel Novel Breast Cancer Strategies
Mutations on the ESR1 gene, which encodes the estrogen receptor, have emerged as an important driver of resistance to endocrine therapies, which form the backbone of treatment for patients with ER-positive, HER2-negative breast cancer.
HER2 Expression Drives Treatment Decisions in Gastric/Esophageal Cancers
Experts in the field of upper gastrointestinal cancers discuss recent data from the European Society for Medical Oncology Congress 2021 that may bolster the uptake of HER2 as a guide for treatment decisions in the second line.
Charting a Path for the Integration of Immunotherapy in the Treatment of Multiple Myeloma
Fenghuang Zhan, MD, PhD, and John D. Shaughnessy, Jr, PhD, discuss the need for a paradigm shift in the treatment of multiple myeloma with the integration of immunotherapy.
Investigators Look to Enhance Outcomes for Unresectable ESCC With Chemoradiation Combination
Since most diagnoses of esophageal squamous cell carcinoma are made when the disease is in advanced stages, investigators have initiated studies to evaluate the efficacy of immunotherapy in earlier lines of therapy, including in combination with chemoradiotherapy.
Oncology Care Evolves as Lasting COVID-19 Effects Come Into Focus
The pandemic appears to have caused or contributed to a number of lasting changes in the way oncologists provide clinical care to their patients.
Optimizing Outcomes With ADCs in Breast Cancer Requires a Tactical Approach
Antibody-drug conjugates are innovative and effective therapeutic agents that have transformed the treatment landscape for patients with HER2-positive breast cancer and triple-negative breast cancer.
Ultra-Rare Sarcoma Subgroup Sees First Treatment Option
Nab-sirolimus became a treatment option for a rare, aggressive soft-tissue sarcoma—malignant perivascular epithelioid cell tumor—following encouraging data in the first prospective clinical trial for this patient population.
Cancer Efforts Face Setback as Ongoing Challenges to Scientific Authority Continue
Maurie Markman, MD, discusses the obstacles presented to cancer efforts as a result of challenges to scientific authority during the COVID-19 pandemic.
Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD
Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers
Dr Ramdial on Gemcitabine/Clofarabine/Busulfan for Lymphoma Stem Cell Transplant
Retrospective Analysis Shows Post-HCT Survival Benefits With Orca-T Vs PTCy in Hematologic Malignancies
2 Commerce Drive Cranbury, NJ 08512